326 related articles for article (PubMed ID: 21114656)
1. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients.
Ferguson R; Grinyó J; Vincenti F; Kaufman DB; Woodle ES; Marder BA; Citterio F; Marks WH; Agarwal M; Wu D; Dong Y; Garg P
Am J Transplant; 2011 Jan; 11(1):66-76. PubMed ID: 21114656
[TBL] [Abstract][Full Text] [Related]
2. Belatacept for kidney transplant recipients.
Masson P; Henderson L; Chapman JR; Craig JC; Webster AC
Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010699. PubMed ID: 25416857
[TBL] [Abstract][Full Text] [Related]
3. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
[TBL] [Abstract][Full Text] [Related]
4. Renal transplantation using belatacept without maintenance steroids or calcineurin inhibitors.
Kirk AD; Guasch A; Xu H; Cheeseman J; Mead SI; Ghali A; Mehta AK; Wu D; Gebel H; Bray R; Horan J; Kean LS; Larsen CP; Pearson TC
Am J Transplant; 2014 May; 14(5):1142-51. PubMed ID: 24684552
[TBL] [Abstract][Full Text] [Related]
5. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study.
Rostaing L; Massari P; Garcia VD; Mancilla-Urrea E; Nainan G; del Carmen Rial M; Steinberg S; Vincenti F; Shi R; Di Russo G; Thomas D; Grinyó J
Clin J Am Soc Nephrol; 2011 Feb; 6(2):430-9. PubMed ID: 21051752
[TBL] [Abstract][Full Text] [Related]
6. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy.
Tsai MK; Wu FL; Lai IR; Lee CY; Hu RH; Lee PH
Int J Artif Organs; 2009 Jun; 32(6):371-80. PubMed ID: 19670189
[TBL] [Abstract][Full Text] [Related]
7. Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study.
Klintmalm GB; Feng S; Lake JR; Vargas HE; Wekerle T; Agnes S; Brown KA; Nashan B; Rostaing L; Meadows-Shropshire S; Agarwal M; Harler MB; Garcia-Valdecasas JC
Am J Transplant; 2014 Aug; 14(8):1817-27. PubMed ID: 25041339
[TBL] [Abstract][Full Text] [Related]
8. Mycophenolate mofetil/sirolimus compared to other common immunosuppressive regimens in kidney transplantation.
Srinivas TR; Schold JD; Guerra G; Eagan A; Bucci CM; Meier-Kriesche HU
Am J Transplant; 2007 Mar; 7(3):586-94. PubMed ID: 17229066
[TBL] [Abstract][Full Text] [Related]
9. De novo low-dose sirolimus versus mycophenolate mofetil in combination with extended-release tacrolimus in kidney transplant recipients: a multicentre, open-label, randomized, controlled, non-inferiority trial.
Huh KH; Lee JG; Ha J; Oh CK; Ju MK; Kim CD; Cho HR; Jung CW; Lim BJ; Kim YS;
Nephrol Dial Transplant; 2017 Aug; 32(8):1415-1424. PubMed ID: 28810721
[TBL] [Abstract][Full Text] [Related]
10. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation.
Rostaing L; Cantarovich D; Mourad G; Budde K; Rigotti P; Mariat C; Margreiter R; Capdevilla L; Lang P; Vialtel P; Ortuño-Mirete J; Charpentier B; Legendre C; Sanchez-Plumed J; Oppenheimer F; Kessler M;
Transplantation; 2005 Apr; 79(7):807-14. PubMed ID: 15818323
[TBL] [Abstract][Full Text] [Related]
11. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model.
Jones-Hughes T; Snowsill T; Haasova M; Coelho H; Crathorne L; Cooper C; Mujica-Mota R; Peters J; Varley-Campbell J; Huxley N; Moore J; Allwood M; Lowe J; Hyde C; Hoyle M; Bond M; Anderson R
Health Technol Assess; 2016 Aug; 20(62):1-594. PubMed ID: 27578428
[TBL] [Abstract][Full Text] [Related]
12. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus.
Gallon LG; Winoto J; Chhabra D; Parker MA; Leventhal JR; Kaufman DB
Transplantation; 2007 May; 83(10):1324-9. PubMed ID: 17519781
[TBL] [Abstract][Full Text] [Related]
13. Belatacept-based immunosuppression with simultaneous calcineurin inhibitor avoidance and early corticosteroid withdrawal: A prospective, randomized multicenter trial.
Woodle ES; Kaufman DB; Shields AR; Leone J; Matas A; Wiseman A; West-Thielke P; Sa T; King EC; Alloway RR;
Am J Transplant; 2020 Apr; 20(4):1039-1055. PubMed ID: 31680394
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial of 3 maintenance regimens (TAC/SRL vs. TAC/MMF vs. CSA/SRL) with low-dose corticosteroids in primary kidney transplantation: 18-year results.
Ciancio G; Gaynor JJ; Guerra G; Roth D; Chen L; Kupin W; Mattiazzi A; Ortigosa-Goggins M; Moni L; Burke GW
Clin Transplant; 2020 Dec; 34(12):e14123. PubMed ID: 33070366
[TBL] [Abstract][Full Text] [Related]
15. Comparison of steroid avoidance in tacrolimus/mycophenolate mofetil and tacrolimus/sirolimus combination in kidney transplantation monitored by surveillance biopsy.
Anil Kumar MS; Heifets M; Fyfe B; Saaed MI; Moritz MJ; Parikh MH; Kumar A
Transplantation; 2005 Sep; 80(6):807-14. PubMed ID: 16210969
[TBL] [Abstract][Full Text] [Related]
16. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option?
Höcker B; Tönshoff B
Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600
[TBL] [Abstract][Full Text] [Related]
17. Conversion from Calcineurin Inhibitor- to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b Trial.
Budde K; Prashar R; Haller H; Rial MC; Kamar N; Agarwal A; de Fijter JW; Rostaing L; Berger SP; Djamali A; Leca N; Allamassey L; Gao S; Polinsky M; Vincenti F
J Am Soc Nephrol; 2021 Dec; 32(12):3252-3264. PubMed ID: 34706967
[TBL] [Abstract][Full Text] [Related]
18. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
19. Long-term renal allograft function on a tacrolimus-based, pred-free maintenance immunosuppression comparing sirolimus vs. MMF.
Gallon L; Perico N; Dimitrov BD; Winoto J; Remuzzi G; Leventhal J; Gaspari F; Kaufman D
Am J Transplant; 2006 Jul; 6(7):1617-23. PubMed ID: 16827862
[TBL] [Abstract][Full Text] [Related]
20. Sirolimus vs mycophenolate moftile in Tacrolimus based therapy following induction with Antithymocyte globulin promotes regulatory T cell expansion and inhibits RORγt and T-bet expression in kidney transplantation.
Jamali S; Sarafnejad A; Ahmadpoor P; Nafar M; Karimi M; Eteghadi A; Yekaninejad MS; Amirzargar AA
Hum Immunol; 2019 Sep; 80(9):739-747. PubMed ID: 30597187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]